Exposiciones: Inicio del tratamiento con agonistas del receptor de GLP-1 (AR-GLP-1) frente a inhibidores de la DPP-4 (IDP-4)
Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct
Wegovy is a GLP-1 receptor agonist (once-weekly injection) that produces about 15% body weight loss, while Contrave is an oral pill combining naltrexone and bupropion that typically produces 5-8% loss
Retatrutide is still in clinical trials, so its full safety profile is not yet known
Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B